Regulatory and safety status: Semax is currently awaiting FDA review
Achieved IgG reduction is similar to that achieved by nipocalimab in human FcRn transgenic mice [360], and a concomitant therapeutic effect has been observed in animal models of arthritis, ITP and glomerulonephritis [414,415,416] and in clinical trials assessing safety (NCT01802697), increasing transplant success by negating pre-existing immunity (NCT02224820, NCT02426684, and NCT02475551), and in thrombotic thrombocytopenic purpura (NCT02854059)
Ceramide NP reinforces moisture barrier function
Ongoing Support As you progress, regular check-ins with your Rixa Health provider ensure your plan remains optimized for maximum effectiveness
Up early, stay regular, no gas, no bloating, no pooping issues